146 related articles for article (PubMed ID: 38564089)
1. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
Lin D; Sturgeon KM; Muscat JE; Zhou S; Hobkirk AL; O'Brien KM; Sandler DP; Thompson CL
Breast Cancer; 2024 May; 31(3):519-528. PubMed ID: 38564089
[TBL] [Abstract][Full Text] [Related]
2. Association between pre-diagnosis recreational physical activity and risk of breast cancer recurrence: the California Teachers Study.
Lin D; Thompson CL; Demalis A; Derbes R; Al-Shaar L; Spielfogel ES; Sturgeon KM
Cancer Causes Control; 2024 Apr; ():. PubMed ID: 38613744
[TBL] [Abstract][Full Text] [Related]
3. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
7. Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis.
Zhang J; Lu CY; Chen CH; Chen HM; Wu SY
Breast; 2020 Dec; 54():70-78. PubMed ID: 32947148
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
Chen HL; Chen Q; Deng YC
Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery.
Zhang J; Lu CY; Chen HM; Wu SY
Surg Oncol; 2021 Mar; 36():91-98. PubMed ID: 33316685
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
11. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
[TBL] [Abstract][Full Text] [Related]
12. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer.
Usiskin I; Li F; Irwin ML; Cartmel B; Sanft T
Breast Cancer; 2019 Nov; 26(6):719-728. PubMed ID: 31119682
[TBL] [Abstract][Full Text] [Related]
13. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
[TBL] [Abstract][Full Text] [Related]
14. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Yang H; Zhou L; Wang S; Cao Y; Tong F; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Guo J; Wang S; Peng Y
Medicine (Baltimore); 2018 Oct; 97(40):e12690. PubMed ID: 30290661
[TBL] [Abstract][Full Text] [Related]
16. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.
Fayanju OM; Ren Y; Suneja G; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Force J; Hyslop T; Hwang ES
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):377-389. PubMed ID: 31678225
[TBL] [Abstract][Full Text] [Related]
17. Response to immunohistochemical markers' conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis.
Zhao Y; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Jan; 22(1):91-102. PubMed ID: 31006089
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
20. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
